Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2015-05-05 Report Publication Anno…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec to report First Quarter 2015 Results on 12 May 2015
Report Publication Announcement Classification · 99% confidence The document is a press release dated May 5, 2015, announcing that Evotec AG will report its financial results for the First Quarter of 2015 on May 12, 2015. It provides details for an accompanying conference call and webcast. This is not the actual financial report (IR or ER), but rather an announcement about *when* the results will be released and discussed. This fits the definition of a Report Publication Announcement (RPA), which signals the upcoming release of a report, or potentially an Earnings Release (ER) if it contained the actual summary results, but since it only announces the date, RPA is more precise. Given the options, RPA is the best fit for an announcement detailing the schedule for releasing financial results.
2015-05-05 English
Evotec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 09.06.2015 in Hamburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 100% confidence The document is explicitly titled 'Bekanntmachung der Einberufung zur Hauptversammlung am 09.06.2015' (Announcement of the Convocation for the Annual General Meeting on June 9, 2015). The content details the agenda (Tagesordnung) for this meeting, including proposals for discharging board members, appointing auditors, electing a new supervisory board member, and approving a conditional capital increase related to a Share Performance Plan. These elements are characteristic of materials prepared for and announced prior to an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2015-04-30 German
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is very short (1363 characters) and announces a change in the 'Total Voting Rights' as of April 30, 2015, citing Article 26a of the WpHG. This type of announcement, detailing the total number of shares with voting rights, is a specific regulatory disclosure. It is not a full report (like 10-K or IR), nor is it a dividend announcement (DIV) or a director's dealing (DIRS). It most closely aligns with a general regulatory announcement or a specific notification regarding share capital/voting rights. Since there is no specific code for 'Total Voting Rights Announcement', and it is a mandatory regulatory disclosure, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for specific regulatory disclosures that don't fit other defined categories. It is not a declaration of voting results (DVA), which typically follows a meeting.
2015-04-30 English
Facio partners with Evotec and initiates FSHD drug discovery programme
Regulatory Filings Classification · 100% confidence The document is a press release dated April 29, 2015, announcing a new drug discovery agreement between Evotec AG and Facio Therapies regarding FSHD. It contains standard press release formatting, including a headline, date, company identifiers (DGAP-News, EQS Group AG), and forward-looking statements. This type of announcement, detailing a strategic partnership or business development without being a full financial report (like 10-K or IR) or a specific regulatory filing like insider trading (DIRS) or dividend notice (DIV), fits best under the general 'Regulatory Filings' category as a miscellaneous corporate announcement, or potentially 'Capital/Financing Update' if it involved funding, but since it's a partnership announcement, RNS is the most appropriate fallback for non-standard news releases not covered by other specific codes like ER or CT. Given the options, RNS (Regulatory Filings / General Regulatory Announcements) is the best fit for a standard corporate news release about a partnership.
2015-04-29 English
Declaration of Voting Results & Voting Rights Announcements 2015
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states 'Voting Rights Announcements' in the header and details notifications regarding the crossing or reaching of voting rights thresholds (10%, 5%) by TVM V Life Science Management GmbH & Co KG concerning Evotec AG, citing German regulatory articles (Art. 25a, Sec. 1 WpHG). This directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Although it is a regulatory announcement, DVA is a more specific category than the general RNS.
2015-03-31 English
Declaration of Voting Results & Voting Rights Announcements 2015
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states in the header and content that it is a "Voting Rights Announcement" pursuant to German Securities Trading Act (WpHG) articles. It details a change in the proportion of voting rights held by TVM V Life Science Ventures GmbH & Co KG, specifically noting that a threshold (10%) was crossed/reached, resulting in a new total voting rights percentage (9.86%). This directly matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short and is a notification, not a comprehensive report.
2015-03-31 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.